In recent years, the prevalence of chronic kidney disease (CKD) has significantly increased, with an estimated 843.6 million individuals affected in 2017 [1]. This rise is closely linked to the growing incidence of risk factors such as diabetes mellitus and obesity. Patients with diabetic kidney disease (DKD), one of the most common complications of diabetes, are characterized by high cardiovascular morbidity and mortality. Recent evidence indicates that sodium-glucose cotransporter 2 inhibitors (SGLT2i) play a crucial role in reducing the progression of both DKD and CKD, thanks to its nephroprotective and cardioprotective effects. SGLT2i work by decreasing glomerular hyperfiltration, improving tubulo-glomerular feedback, and reducing blood glucose levels.
Keywords: CKD; SGLT2i; hyperfiltration; nephroprotection; proteinuria.
Copyright by Società Italiana di Nefrologia SIN, Rome, Italy.